Albers Jeffrey W. 4

What Happened

• Jeffrey W. Albers, a director of Spyre Therapeutics (SYRE), was granted a derivative award on 2026-05-27: an option representing the right to purchase 8,026 shares of common stock. The filing shows the reported price as $0.00 and lists the transaction type as an award/grant (A). This is a grant of an option/award, not an immediate purchase or sale of shares, so there was no cash exchanged at grant.

Key Details

• Transaction date: 2026-05-27; Form 4 filed: 2026-05-29 (filed within the typical 2-business-day window).
• Award: option to purchase 8,026 shares; reported price: $0.00 (derivative grant).
• Vesting: the option vests and becomes fully exercisable upon the earlier of May 27, 2027 or the Issuer’s 2027 annual meeting of stockholders, subject to Albers’ continuous service (per footnote).
• Shares owned after the transaction: not specified in the Form 4 filing.
• Transaction code: A = Award/Grant (derivative instrument).

Context

• This was a time‑vesting option grant (a future right to buy shares) rather than an exercise or market sale. The grant does not represent immediate ownership or proceeds; value will depend on future stock price and any exercise terms when/if the option vests and is exercised.